Two Onc Docs

ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC

Season 3 Episode 17

This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.